BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]
, 2012 MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Jørgensen, Heather G. +18 more
core +1 more source
Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy [PDF]
, 2014 This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). © 2014 Baishideng Publishing Group Inc.There have been significant improvements in the detection
Hussain, HA, Harvey, A
core +1 more source
BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]
, 2009 Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is ...
van, Loo PF, Hendriks, RW
core +1 more source
Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation [PDF]
, 2014 Casein kinase 2 (protein kinase CK2) is a conserved eukaryotic serine/theronine kinase with multiple substrates and roles in the regulation of cellular processes such as cellular stress, cell proliferation and apoptosis.
Schmid, Ralf +8 more
core +3 more sources
Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
Hematology/Oncology and Stem Cell Therapy, 2023 The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment.
Guru Subramanian Guru Murthy +1 more
doaj +1 more source
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Drug Design, Development and Therapy, 2022 Edgar Carnero Contentti,1 Jorge Correale2,3 1Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina; 2Department of Neurology, Fleni, Buenos Aires, Argentina; 3Universidad de Buenos Aires-CONICET, Instituto de ...
Carnero Contentti E, Correale J
doaj
EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5 [PDF]
, 2013 Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in invasion of tumor cells.
Geiszt, Miklós +5 more
core +1 more source
Indian Journal of Medical and Paediatric Oncology, 2020 Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.
Parathan Karunakaran
doaj +1 more source
Abnormalities affecting tyrosine kinase signalling in atypical myeloproliferative disorders [PDF]
, 2009 The myeloproliferative disorders (MPDs) are a group of haematopoietic stem cell diseases, characterised by proliferation of one or more cells of the myeloid lineage.
Hidalgo-Curtis, Claire
core +1 more source
Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
eJHaem, 2021 All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK‐1026.
Bibian M.E. Tullemans +13 more
doaj +1 more source